Shares of Agilent Technologies climbed to a 52-week high of $169.07 on Monday, with the stock trading around $168.76 and a market capitalization of $46.98 billion.
The milestone comes on the heels of the company's fiscal third-quarter earnings release and a wave of analyst price-target increases, all pointing to sustained momentum in its analytical instruments and life sciences businesses.
For the quarter, Agilent reported adjusted earnings of $1.62 per share and revenue of $1.88 billion, with organic growth coming in at 7.3%. The results topped expectations and were accompanied by raised guidance for the full year.
The positive data drew swift reactions from several Wall Street firms. Bernstein raised its price target to $180, citing the third-quarter earnings beat and robust organic growth. TD Cowen also lifted its target to $180, highlighting strength across revenue, margins and earnings per share.
RBC Capital increased its target to $185, pointing to the quarterly beat and improved outlook. Stifel set a $180 target, noting particularly strong performance in liquid chromatography-mass spectrometry (LC-MS) and Advanced Therapeutics divisions.
According to InvestingPro analysis, 11 analysts have revised their earnings estimates upward for the upcoming period.
The stock has gained 37.56% over the past year and surged 45.37% over the last six months, outpacing broader market returns and reinforcing investor appetite for the analytical-instrument maker.
